Guided Therapeutics (GTHP) 0.0443 $GTHP
Study Finds Guided Therapeutics' LuViva(R) Advanced Cervical Scan Can Predict Future Worsening of Precancer
Business Wire - Thu Oct 08, 7:05AM CDT
Results of a study presented at a major international women's health conference indicate that the LuViva(R) Advanced Cervical Scan was able predict which women would progress from mild cervical abnormalities to more severe forms of the disease that require treatment. The LuViva was developed and is made by Guided Therapeutics, Inc. (OTCQB:GTHP).
2016 Emerging Cancer Diagnostic Tests, and Strategic Profiles of Leading Reagent and Instrument Suppliers
M2 - Tue Oct 06, 8:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft8w4r/2016_emerging) has announced the addition of the "2016 Emerging Cancer Diagnostic Tests, and Strategic Profile of Leading Reagent and Instrument Suppliers" report to their offering. This 286-page report presents comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects, for the major categories of both circulating and cellular tests, such as Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others. The report includes an overview of the clinical significance and market needs for both current and emerging cancer diagnostic tests, as well as extensive listings of companies, universities and research centers developing or marketing new technologies, products, and applications. The report also presents strategic assessments of current and emerging suppliers of cancer diagnostic products, including their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Decode Genetics - Diadexus - Epigenomics - Enterix - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Qiagen - Quest Diagnostics - Roche - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Zila For more information visit http://www.researchandmarkets.com/research/ft...6_emerging
MYGN: 39.19 (-0.19), A: 36.23 (+0.22), DGX: 63.26 (+0.26), DHR: 88.51 (-0.38), HOLX: 37.28 (+0.08)
2015-2019 Cancer Diagnostics: A Market on the Verge of Explosion - Technological Breakthroughs, Emerging Tests, Market Forecasts & Competitive Intelligence
M2 - Thu Oct 01, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lnhtf8/20152019_cancer) has announced the addition of the "2015-2019 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence" report to their offering. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Worldwide Market Overview - Five-year test volume and sales projections by country. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country. - Estimated universe of laboratories performing cancer diagnostic testing by country. - Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan. The companies analyzed in the report include - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Diadexus - Diagnocure - DiaSorin - Eiken Chemical - Elitech Group - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/ln...019_cancer
A: 36.23 (+0.22), DGX: 63.26 (+0.26), CPHD: 43.60 (-0.33), DHR: 88.51 (-0.38), HOLX: 37.28 (+0.08)
Guided Therapeutics reports shipment of first four LuViva Advanced Cervical Scans for USD14m to Turkey
M2 - Thu Oct 01, 6:20AM CDT
Guided Therapeutics (OTCBB:GTHP), provider of a rapid and painless testing platform based on its patented biophotonic technology, disclosed on Wednesday that it has delivered the first four LuViva Advance Cervical Scan units to its Turkish distributor under its agreement with the Turkish Ministry of Health (MOH).
Guided Therapeutics Ships First Four LuViva(R) Advanced Cervical Scans for $14 million Turkish Ministry of Health Order
Business Wire - Wed Sep 30, 7:06AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has shipped the first four LuViva(R) Advance Cervical Scan units to its Turkish distributor for its order with the Turkish Ministry of Health (MOH).
Guided Therapeutics to Present at 2015 Aegis Growth Conference
Business Wire - Wed Sep 23, 6:59AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid, point of care cervical cancer testing platform based on its patented biophotonic technology, announced today that it will be presenting at the 2015 Aegis Growth Conference to be held October 7-9, 2015 at the Encore at Wynn Las Vegas, Las Vegas, NV.
Guided Therapeutics and U.S. FDA Agree on Meeting Date to Plan Path Forward for LuViva(R) Advanced Cervical Scan Premarket Approval Application
Business Wire - Tue Sep 15, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it will meet with the U.S. Food and Drug Administration (FDA) November 6, 2015, to review the company's plan to submit an approvable application for the LuViva(R) Advanced Cervical Scan.
Gynecological Devices Market Analysis 2015-2020 - Vaginal Speculum, Examination Chairs, Cervical Dilators, Ablation and Fluid Management Devices
M2 - Tue Sep 15, 4:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s5fdkz/gynecological) has announced the addition of the "Gynecological Devices Market Analysis (2015 - 2020); Endoscope Types (Colposcopies, Laparoscopes, Resect scopes); By Devices (Vaginal Speculum, Examination Chairs, Cervical Dilators, Ablation and Fluid Management Devices)" report to their offering. Gynecology is the area of medicine that involves practices dealing with the health of the female reproductive system. Gynaecology devices market is rapidly growing market of health sector due to increase in female related disorders and ageing population as well. The gynaecological device market is classified on the basis of types of endoscopes, types of cervical dilators, endometrial ablation devices, gynaecological examination couch, fluid management system, gynaecological implants and female sterilization and contraceptive devices. The report investigates current state of gynaecology device market & examines the predicted future advancements in this market. The report also analyses the market depending on major geographies and give details of key players engaged in manufacturing of diagnostic devices. It provides a technological growth map over time to understand the industry growth rate. Key Topics Covered: 1. Gynaecological Devices- Market Overview 2. Executive Summary 3. Gynaecological Devices- Market Landscape 4. Gynaecological Devices - Market Forces 5. Gynaecological Devices Market - Strategic Analysis 6. Gynaecological Devices Market - By Types of Endoscopes 7. Gynaecological Devices Market- By Devices 8. Gynaecological Devices market- By End Users 9. Gynaecological Devices market- by Geography 10. Company Profiles - Bayer AG - Boston Scientific Corporation - Wallach & Company, Inc. - Medtronic Inc. - Stryker Corp. - Ethicon Inc. - Conceptus Inc. - CooperSurgical Inc. - Olympus Corporation - Nucletron B.V - Becton Dickinson & Co - Misonix - Femcare-Nikomed - Guided Therapeutics - Intuitive Surgical - Meditelle Medical Equipment Ltd. - KARL STORZ GmbH & CoKG For more information visit http://www.researchandmarkets.com/research/s5...ecological
ISRG: 469.65 (+1.24), BSX: 16.88 (+0.09), BDX: 137.76 (+0.64), MDT: 72.60 (+0.55), MSON: 10.76 (-0.06), SYK: 97.75 (+0.40)
Guided Therapeutics' Turkish Distributor Doubles Order for LuViva(R) Advanced Cervical Scan Single-Use Disposables for Turkish Ministry of Health
Business Wire - Wed Sep 09, 7:14AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that its Turkish distributor, ITEM Medical Technologies, has received an increased order for disposable Cervical Guides from the Turkish Ministry of Health (MOH).
Guided Therapeutics Announces $550,000 Increase to $4 Million Private Placement and Accelerated Interim Closing
Business Wire - Thu Sep 03, 10:03AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP) announced today that it has entered into an amendment agreement to increase by $550,000 the gross cash proceeds from its previously announced private placement of convertible preferred stock and common stock warrants, as well as to accelerate the closing of $1.3 million of the total $4.55 million investment. Among those making the additional investment is a member of the Company's Board of Directors.
Guided Therapeutics Expands Access of the LuViva(R) Advanced Cervical Scan into Costa Rica
Business Wire - Tue Aug 25, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP) announced today that access to the LuViva(R) Advanced Cervical Scan has been expanded to Costa Rica, bringing to 20 the number of countries where the Company has shipped its non-invasive, point-of-care cervical cancer detection technology.
Guided Therapeutics Submits Proposal to Kenya to Increase Cervical Cancer Screening Rates - Potential Screening Population of 12 Million Women
Business Wire - Thu Aug 20, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), in cooperation with its distributor, Stem World Enterprises, is working with the Kenyan National Ministry of Health (MOH) to help achieve First Lady Margret Kenyatta's Beyond Zero program goal of screening up to 12,000,000 Kenyan women for cervical cancer. President Uhuru Kenyatta himself has set a target of screening half the female population for cervical cancer each year.
Guided Therapeutics Advances LuViva PMA Application with FDA
Business Wire - Tue Aug 18, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP) today announced that it has presented the U.S. Food and Drug Administration (FDA) with a plan for advancing the pre-market approval (PMA) application for the LuViva(R) Advanced Cervical Scan. In its "pre-submission" letter, the Company also requested a meeting with the agency to finalize the plan.
Strategies in the Global Tumor Marker Testing Market 2015 - Forecasts Sales of Major Tumor Markers by Country and Market Segment
M2 - Thu Aug 13, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjr4qj/2015_strategies) has announced the addition of the "2015 Strategies in the Global Tumor Marker Testing Market: US, Europe, Japan" report to their offering. Highlights Identifies and evaluates major business opportunities emerging in the tumor marker market during the next five years. Examines trends in the U.S., Europe and Japan Reviews current and emerging tumor markers. Analyzes applications of emerging diagnostic technologies. Forecasts sales of major tumor markers by country and market segment. Profiles leading market players and potential entrants Companies Mentioned: - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics For more information visit http://www.researchandmarkets.com/research/vj...strategies
MYGN: 39.19 (-0.19), ENZ: 3.75 (+0.04), A: 36.23 (+0.22), CPHD: 43.60 (-0.33), DHR: 88.51 (-0.38), HOLX: 37.28 (+0.08)
Guided Therapeutics Reports Second Quarter 2015 Financial Results; Closes $10 Million Deal
Business Wire - Wed Aug 12, 3:05PM CDT
--$10 million deal with Turkey Ministry of Health for cervical cancer screening
Guided Therapeutics Schedules Conference Call to Discuss Second Quarter 2015 Financial Results
Business Wire - Tue Aug 04, 1:02PM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it will report its 2015 second quarter financial results following the market close on Wednesday, August 12, 2015. The Company has scheduled a conference call for Thursday, August 13, 2015 at 11:00 A.M. Eastern Time (ET) to review the results.
Guided Therapeutics' Distributor Signs New Four-year Deal to Sell $10 Million of LuViva(R) Advanced Cervical Scans to Turkish Ministry of Health
Business Wire - Tue Jul 28, 7:04AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that its Turkish distributor, ITEM Medical Technologies, has been awarded a new, four-year contract to supply LuViva(R) Advanced Cervical Scans and single-use, disposable Screening Cervical Guides to the Turkish Ministry of Health (MOH). The contract will generate more than $10 million for Guided Therapeutics.
Guided Therapeutics Announces $4 Million Private Placement
Business Wire - Tue Jun 30, 7:30AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that it has entered into a securities purchase agreement with certain accredited investors for the private placement of its convertible preferred stock and warrants to purchase shares of its common stock. Gross cash proceeds to the Company are expected to be approximately $4.0 million, prior to the payment of placement agent fees and expenses.
2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations
M2 - Mon Jun 29, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phj84s/2015_market) has announced the addition of the "2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations" report to their offering. 2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations is a new study of the major business opportunities emerging in the US cancer diagnostics market during the nextfive years. The report examines trends in the US market; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the US cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. US Market Overview - Five-year test volume and sales projections. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Estimated universe of laboratories performing cancer diagnostic testing. - Cancer statistics, etiology and recent developments in the US. Business Opportunities and Strategic Recommendations - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test - Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines Supplier Shares, Sales and Volume Forecasts - Sales and market shares of major cancer diagnostic product suppliers by individual test. - Five-year test volume and sales forecasts for major tumor markers by market segment, including: - Hospitals - Commercial/Private Laboratories - Physician Offices/Group Practices - Cancer Clinics - Ambulatory Care Centers Instrumentation Review - Analysis of major molecular diagnostic and immunodignostic analyzers used for cancer testing, including their operating characteristics, features and selling prices. Technology Assessment - Assessment of latest technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies. - Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies - Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Companies Mentioned - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Veridex - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/ph...015_market
MYGN: 39.19 (-0.19), ENZ: 3.75 (+0.04), A: 36.23 (+0.22), CPHD: 43.60 (-0.33), DHR: 88.51 (-0.38), HOLX: 37.28 (+0.08)
2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence
M2 - Thu Jun 18, 12:14PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x472n5/2015_cancer) has announced the addition of the "2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Geographic Coverage France, Germany, Italy, Japan, Spain, UK, USA - The companies analyzed in the report include - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/x4...015_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MYGN: 39.19 (-0.19), A: 36.23 (+0.22), DHR: 88.51 (-0.38), SQNM: 2.11 (+0.01), ENZ: 3.75 (+0.04), DGX: 63.26 (+0.26), CPHD: 43.60 (-0.33), HOLX: 37.28 (+0.08)
Study Finds Guided Therapeutics' LuViva(R) Advanced Cervical Scan Can Predict Future Worsening of Precancer
Business Wire - Thu Oct 08, 7:05AM CDT
Results of a study presented at a major international women's health conference indicate that the LuViva(R) Advanced Cervical Scan was able predict which women would progress from mild cervical abnormalities to more severe forms of the disease that require treatment. The LuViva was developed and is made by Guided Therapeutics, Inc. (OTCQB:GTHP).
2016 Emerging Cancer Diagnostic Tests, and Strategic Profiles of Leading Reagent and Instrument Suppliers
M2 - Tue Oct 06, 8:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ft8w4r/2016_emerging) has announced the addition of the "2016 Emerging Cancer Diagnostic Tests, and Strategic Profile of Leading Reagent and Instrument Suppliers" report to their offering. This 286-page report presents comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects, for the major categories of both circulating and cellular tests, such as Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others. The report includes an overview of the clinical significance and market needs for both current and emerging cancer diagnostic tests, as well as extensive listings of companies, universities and research centers developing or marketing new technologies, products, and applications. The report also presents strategic assessments of current and emerging suppliers of cancer diagnostic products, including their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Companies Mentioned - Abbott - AdnaGen/Alere - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Decode Genetics - Diadexus - Epigenomics - Enterix - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Qiagen - Quest Diagnostics - Roche - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Zila For more information visit http://www.researchandmarkets.com/research/ft...6_emerging
MYGN: 39.19 (-0.19), A: 36.23 (+0.22), DGX: 63.26 (+0.26), DHR: 88.51 (-0.38), HOLX: 37.28 (+0.08)
2015-2019 Cancer Diagnostics: A Market on the Verge of Explosion - Technological Breakthroughs, Emerging Tests, Market Forecasts & Competitive Intelligence
M2 - Thu Oct 01, 9:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lnhtf8/20152019_cancer) has announced the addition of the "2015-2019 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence" report to their offering. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Worldwide Market Overview - Five-year test volume and sales projections by country. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country. - Estimated universe of laboratories performing cancer diagnostic testing by country. - Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan. The companies analyzed in the report include - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Diadexus - Diagnocure - DiaSorin - Eiken Chemical - Elitech Group - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/ln...019_cancer
A: 36.23 (+0.22), DGX: 63.26 (+0.26), CPHD: 43.60 (-0.33), DHR: 88.51 (-0.38), HOLX: 37.28 (+0.08)
Guided Therapeutics reports shipment of first four LuViva Advanced Cervical Scans for USD14m to Turkey
M2 - Thu Oct 01, 6:20AM CDT
Guided Therapeutics (OTCBB:GTHP), provider of a rapid and painless testing platform based on its patented biophotonic technology, disclosed on Wednesday that it has delivered the first four LuViva Advance Cervical Scan units to its Turkish distributor under its agreement with the Turkish Ministry of Health (MOH).
Guided Therapeutics Ships First Four LuViva(R) Advanced Cervical Scans for $14 million Turkish Ministry of Health Order
Business Wire - Wed Sep 30, 7:06AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has shipped the first four LuViva(R) Advance Cervical Scan units to its Turkish distributor for its order with the Turkish Ministry of Health (MOH).
Guided Therapeutics to Present at 2015 Aegis Growth Conference
Business Wire - Wed Sep 23, 6:59AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid, point of care cervical cancer testing platform based on its patented biophotonic technology, announced today that it will be presenting at the 2015 Aegis Growth Conference to be held October 7-9, 2015 at the Encore at Wynn Las Vegas, Las Vegas, NV.
Guided Therapeutics and U.S. FDA Agree on Meeting Date to Plan Path Forward for LuViva(R) Advanced Cervical Scan Premarket Approval Application
Business Wire - Tue Sep 15, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it will meet with the U.S. Food and Drug Administration (FDA) November 6, 2015, to review the company's plan to submit an approvable application for the LuViva(R) Advanced Cervical Scan.
Gynecological Devices Market Analysis 2015-2020 - Vaginal Speculum, Examination Chairs, Cervical Dilators, Ablation and Fluid Management Devices
M2 - Tue Sep 15, 4:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s5fdkz/gynecological) has announced the addition of the "Gynecological Devices Market Analysis (2015 - 2020); Endoscope Types (Colposcopies, Laparoscopes, Resect scopes); By Devices (Vaginal Speculum, Examination Chairs, Cervical Dilators, Ablation and Fluid Management Devices)" report to their offering. Gynecology is the area of medicine that involves practices dealing with the health of the female reproductive system. Gynaecology devices market is rapidly growing market of health sector due to increase in female related disorders and ageing population as well. The gynaecological device market is classified on the basis of types of endoscopes, types of cervical dilators, endometrial ablation devices, gynaecological examination couch, fluid management system, gynaecological implants and female sterilization and contraceptive devices. The report investigates current state of gynaecology device market & examines the predicted future advancements in this market. The report also analyses the market depending on major geographies and give details of key players engaged in manufacturing of diagnostic devices. It provides a technological growth map over time to understand the industry growth rate. Key Topics Covered: 1. Gynaecological Devices- Market Overview 2. Executive Summary 3. Gynaecological Devices- Market Landscape 4. Gynaecological Devices - Market Forces 5. Gynaecological Devices Market - Strategic Analysis 6. Gynaecological Devices Market - By Types of Endoscopes 7. Gynaecological Devices Market- By Devices 8. Gynaecological Devices market- By End Users 9. Gynaecological Devices market- by Geography 10. Company Profiles - Bayer AG - Boston Scientific Corporation - Wallach & Company, Inc. - Medtronic Inc. - Stryker Corp. - Ethicon Inc. - Conceptus Inc. - CooperSurgical Inc. - Olympus Corporation - Nucletron B.V - Becton Dickinson & Co - Misonix - Femcare-Nikomed - Guided Therapeutics - Intuitive Surgical - Meditelle Medical Equipment Ltd. - KARL STORZ GmbH & CoKG For more information visit http://www.researchandmarkets.com/research/s5...ecological
ISRG: 469.65 (+1.24), BSX: 16.88 (+0.09), BDX: 137.76 (+0.64), MDT: 72.60 (+0.55), MSON: 10.76 (-0.06), SYK: 97.75 (+0.40)
Guided Therapeutics' Turkish Distributor Doubles Order for LuViva(R) Advanced Cervical Scan Single-Use Disposables for Turkish Ministry of Health
Business Wire - Wed Sep 09, 7:14AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that its Turkish distributor, ITEM Medical Technologies, has received an increased order for disposable Cervical Guides from the Turkish Ministry of Health (MOH).
Guided Therapeutics Announces $550,000 Increase to $4 Million Private Placement and Accelerated Interim Closing
Business Wire - Thu Sep 03, 10:03AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP) announced today that it has entered into an amendment agreement to increase by $550,000 the gross cash proceeds from its previously announced private placement of convertible preferred stock and common stock warrants, as well as to accelerate the closing of $1.3 million of the total $4.55 million investment. Among those making the additional investment is a member of the Company's Board of Directors.
Guided Therapeutics Expands Access of the LuViva(R) Advanced Cervical Scan into Costa Rica
Business Wire - Tue Aug 25, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP) announced today that access to the LuViva(R) Advanced Cervical Scan has been expanded to Costa Rica, bringing to 20 the number of countries where the Company has shipped its non-invasive, point-of-care cervical cancer detection technology.
Guided Therapeutics Submits Proposal to Kenya to Increase Cervical Cancer Screening Rates - Potential Screening Population of 12 Million Women
Business Wire - Thu Aug 20, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), in cooperation with its distributor, Stem World Enterprises, is working with the Kenyan National Ministry of Health (MOH) to help achieve First Lady Margret Kenyatta's Beyond Zero program goal of screening up to 12,000,000 Kenyan women for cervical cancer. President Uhuru Kenyatta himself has set a target of screening half the female population for cervical cancer each year.
Guided Therapeutics Advances LuViva PMA Application with FDA
Business Wire - Tue Aug 18, 7:05AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP) today announced that it has presented the U.S. Food and Drug Administration (FDA) with a plan for advancing the pre-market approval (PMA) application for the LuViva(R) Advanced Cervical Scan. In its "pre-submission" letter, the Company also requested a meeting with the agency to finalize the plan.
Strategies in the Global Tumor Marker Testing Market 2015 - Forecasts Sales of Major Tumor Markers by Country and Market Segment
M2 - Thu Aug 13, 10:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjr4qj/2015_strategies) has announced the addition of the "2015 Strategies in the Global Tumor Marker Testing Market: US, Europe, Japan" report to their offering. Highlights Identifies and evaluates major business opportunities emerging in the tumor marker market during the next five years. Examines trends in the U.S., Europe and Japan Reviews current and emerging tumor markers. Analyzes applications of emerging diagnostic technologies. Forecasts sales of major tumor markers by country and market segment. Profiles leading market players and potential entrants Companies Mentioned: - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Guided Therapeutics - Hologic/Gen-Probe - Kreatech - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics For more information visit http://www.researchandmarkets.com/research/vj...strategies
MYGN: 39.19 (-0.19), ENZ: 3.75 (+0.04), A: 36.23 (+0.22), CPHD: 43.60 (-0.33), DHR: 88.51 (-0.38), HOLX: 37.28 (+0.08)
Guided Therapeutics Reports Second Quarter 2015 Financial Results; Closes $10 Million Deal
Business Wire - Wed Aug 12, 3:05PM CDT
--$10 million deal with Turkey Ministry of Health for cervical cancer screening
Guided Therapeutics Schedules Conference Call to Discuss Second Quarter 2015 Financial Results
Business Wire - Tue Aug 04, 1:02PM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it will report its 2015 second quarter financial results following the market close on Wednesday, August 12, 2015. The Company has scheduled a conference call for Thursday, August 13, 2015 at 11:00 A.M. Eastern Time (ET) to review the results.
Guided Therapeutics' Distributor Signs New Four-year Deal to Sell $10 Million of LuViva(R) Advanced Cervical Scans to Turkish Ministry of Health
Business Wire - Tue Jul 28, 7:04AM CDT
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that its Turkish distributor, ITEM Medical Technologies, has been awarded a new, four-year contract to supply LuViva(R) Advanced Cervical Scans and single-use, disposable Screening Cervical Guides to the Turkish Ministry of Health (MOH). The contract will generate more than $10 million for Guided Therapeutics.
Guided Therapeutics Announces $4 Million Private Placement
Business Wire - Tue Jun 30, 7:30AM CDT
Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) announced today that it has entered into a securities purchase agreement with certain accredited investors for the private placement of its convertible preferred stock and warrants to purchase shares of its common stock. Gross cash proceeds to the Company are expected to be approximately $4.0 million, prior to the payment of placement agent fees and expenses.
2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations
M2 - Mon Jun 29, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phj84s/2015_market) has announced the addition of the "2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations" report to their offering. 2015 Market Segmentation Analysis of the US Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Hospitals, Commercial Labs, POC Locations is a new study of the major business opportunities emerging in the US cancer diagnostics market during the nextfive years. The report examines trends in the US market; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the US cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. US Market Overview - Five-year test volume and sales projections. - Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. - Estimated universe of laboratories performing cancer diagnostic testing. - Cancer statistics, etiology and recent developments in the US. Business Opportunities and Strategic Recommendations - Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Test - Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines Supplier Shares, Sales and Volume Forecasts - Sales and market shares of major cancer diagnostic product suppliers by individual test. - Five-year test volume and sales forecasts for major tumor markers by market segment, including: - Hospitals - Commercial/Private Laboratories - Physician Offices/Group Practices - Cancer Clinics - Ambulatory Care Centers Instrumentation Review - Analysis of major molecular diagnostic and immunodignostic analyzers used for cancer testing, including their operating characteristics, features and selling prices. Technology Assessment - Assessment of latest technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies. - Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies - Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Companies Mentioned - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Veridex - Wako Pure Chemicals - Wallac/PE - Zilla For more information visit http://www.researchandmarkets.com/research/ph...015_market
MYGN: 39.19 (-0.19), ENZ: 3.75 (+0.04), A: 36.23 (+0.22), CPHD: 43.60 (-0.33), DHR: 88.51 (-0.38), HOLX: 37.28 (+0.08)
2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence
M2 - Thu Jun 18, 12:14PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x472n5/2015_cancer) has announced the addition of the "2015 Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence" report to their offering. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field.Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Geographic Coverage France, Germany, Italy, Japan, Spain, UK, USA - The companies analyzed in the report include - Abbott - AdnaGen - Agilent Technologies - Applied Gene Technologies - Arca Pharma - Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Correlogic Systems/Vermillion - Decode Genetics - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Elitech Group - Epigenomics - Enterix - Enzo Biochem - Exact Sciences - Fujirebio - Guided Therapeutics - Hologic/Gen-Probe - Kreatech/Leica - Kyowa Medex - Mackay Life Sciences - Myriad Genetics - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Quest Diagnostics - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Thermo Fisher - Tosoh - Veridex - Wako Pure Chemicals - Wallac/PE - Zila For more information visit http://www.researchandmarkets.com/research/x4...015_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MYGN: 39.19 (-0.19), A: 36.23 (+0.22), DHR: 88.51 (-0.38), SQNM: 2.11 (+0.01), ENZ: 3.75 (+0.04), DGX: 63.26 (+0.26), CPHD: 43.60 (-0.33), HOLX: 37.28 (+0.08)
